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Comment on: “HCV modifies EGF signaling and upregulates production of CXCR2 ligands: role 
in inflammation and antiviral immune response” by Christina Groepper, Kerstin Rufinatscha, 
Nadja Schröder, Sabine Stindt, Christian Ehlting, Ute Albrecht, Hans H. Bock, Ralf 
Bartenschlager, Dieter Häussinger and Johannes G. Bode, published in Journal of Hepatology 
2018. 
 
Chronic hepatitis C virus infection (HCV) affects approximately 71 million individuals 
worldwide [1], being a major etiological factor for the development of liver cirrhosis and 
hepatocellular carcinoma (HCC). Acute HCV infection often progresses to chronicity and is 
characterized by a non-resolving liver inflammation leading to a broad range of alterations in the 
tissue microenvironment. About ninety percent of HCC cases arise in the context of chronic liver 
inflammation, highlighting the central role of this persistent immune response in disease 
pathogenesis [2]. Despite efficient antiviral therapy by direct acting antivirals (DAA), the risk of 
HCC development cannot be fully eliminated in patients with advanced liver disease [3]. In this 
regard, accumulating evidence suggests a potentially persisting proto-oncogenic environment 
created by virus-induced changes in the cell signaling [4-7]. Therefore, even in the DAA era, the 
understanding of virus-host interactions during chronic HCV-associated inflammation is key to 
identify and treat patients at high risk to develop HCC. 
In this context, a recent article in Journal of Hepatology by Johannes G. Bode’s 
laboratory at the Heinrich-Heine University in Germany provides a novel mechanism by which 
HCV infection contributes to this pathologic inflammatory response [8]. Aiming to identify 
chemokines regulated by HCV, the authors performed a functional screen using an HCV 
subgenomic replicon system and identified an HCV-induced upregulation of C-X-C motif 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
chemokine receptor 2 (CXCR2) ligands (CXCLs) 1, 2, 3 and 8. Consistently, similar results were 
obtained upon HCV infection using the cell culture-derived strain JC1. Having previously shown 
that HCV infection enhances epidermal growth factor (EGF) signaling, the authors next explored 
the possible involvement of this pathway on CXCR2 ligand expression. EGFR perturbation 
studies combining RNAi knockdown of EGF and the use of MAPK inhibitors, confirmed an 
HCV-induced upregulation of CXCL8 via EGFR and the MAP kinase kinase MEK1. 
Additionally, knockdown of the p65 subunit of the NF-κB complex was sufficient to abrogate 
basal and EGF-induced CXCL8 expression in replicon-expressing cells, while in HCV-infected 
cells this mainly affected basal CXCL8 levels. This suggests that the observed enhancement of 
chemokine expression during HCV infection not only depends on the EGFR pathway but also on 
the activation of additional transcription factors such as NF-κB. The in vivo relevance of the data 
is emphasized by an association of HCV viral load with CXCL8 serum levels in chronically 
infected patients. Similarly, serum levels of EGF and CXCL8 tend to positively correlate 
although this did not reach statistical significance in their study cohort. 
In a previous study, the authors demonstrated that HCV enhances EGFR signaling via NS3/4A-
mediated proteolytic cleavage of T-cell protein tyrosine phosphatase (TC-PTP), one of the major 
negative regulators of EGFR tyrosine-kinase activity [9]. Indeed, here they demonstrate that 
NS3/4A expression alone enhances EGF-inducible CXCL8 expression, an effect that can be 
mimicked by knocking down TC-PTP. As the major role of chemokines is the recruitment of 
immune cells to the site of inflammation, the authors next evaluated if in the context of HCV 
replication EGF-induced release of chemokines influences leukocyte migration. Remarkably, the 
authors demonstrate that media from EGF-treated cell lines expressing the HCV subgenomic 
replicon enhances the migration of neutrophils, an effect that was not observed with EGF-
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conditioned media alone. This suggests that HCV infection modulates chemoattraction of 
immune cells to the liver via EGF-regulated chemokine secretion. 
The findings of Christina Groepper and co-workers are not just relevant for our 
understanding of HCV-EGFR interaction but most importantly provide insight into the 
pathologic consequences of derailed EGF signaling for liver inflammation and HCC 
development (Fig. 1). EGFR is a host factor for HCV by facilitating the assembly of the host 
entry complex, viral glycoprotein-dependent membrane fusion and cell-to-cell transmission of 
the virus [7]. HCV requires EGFR signaling to maintain its life cycle but also induces these 
signals itself during binding to the receptor complex [6, 10]. Moreover, during HCV infection 
the non-structural protein NS5A prolongs EGFR signaling by perturbing its internalization and 
subsequent degradation [11, 12]. This leads to a persistent EGFR activation during chronic HCV 
infection that potentially contributes to an impaired antiviral response by modulating interferon 
alpha signaling via STAT3 [13]. 
Their finding that HCV replication promotes EGF expression is highly relevant in the study of 
HCV-induced chronic liver disease, as the EGF pathway is a key driver associated with 
progression towards cirrhosis [14] and HCC development [15]. Equally interesting is the 
observation that HCV-induced EGF expression is a regulator of CXCR2 ligands. For example, 
HCV infection has been previously described to promote CXCL8 expression, which inhibits 
interferon antiviral activity and facilitates viral infection [16]. Hepatic CXCL8 is detected at low 
maintenance levels during acute HCV infection, although marked increases in serum and hepatic 
levels have been observed in HCV-infected patients with progressive inflammation and cirrhosis 
[17]. Indeed, CXCL8, which is associated with poor outcome in HCC patients, has been 
suggested as HCC biomarker [18]. Here, Groepper and co-workers validated a mechanistic 
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concept between EGFR signaling and CXCL8 during HCV infection, that has been previously 
proposed for hepatomas [19]. Moreover, they provide a previously undescribed mechanism 
linking EGFR signaling to chemoattraction of immune cells. In macrophages EGFR knockout 
attenuates HCC development in mice [20]. EGF-mediated recruitment of neutrophils during 
HCV infection is potentially relevant for liver pathobiology, since it has detrimental effects on 
the host by contributing to the necro-inflammatory process [21]. 
Although further studies in larger patient cohorts are needed to consolidate the model 
proposed by Groepper and co-workers, the impact of their findings for liver disease and its 
association to EGF signaling is evident [22]. In future studies, it would be very interesting and 
potentially relevant to follow up HCV-induced EGF expression pattern in liver tissue and blood 
samples before and after sustained viral response and to compare them to liver fibrosis scores. 
Furthermore, does HCV genotype influences EGF and chemokine expression profiles since 
genotype 3 is associated with more severe liver disease manifestations? Taken together, this 
paper represents a further corroboration for the clinical potential of HCC chemo-preventive 
strategies based on regulators of signal transduction. Indeed, EGFR which is phosphorylated in 
hepatic stellate cells (HSCs) has been successfully targeted by the clinical EGFR inhibitor 
erlotinib in animal models, demonstrating proof of concept that EGF-based therapies attenuates 
chemically induced liver fibrosis and HCC nodules [14]. Therefore, EGFR or MAPK modulators 
could be part of a personalized immuno-therapeutic strategy modulating chemokine profiles and 
inflammatory responses associated with liver disease progression. 
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Figure 1: Refined model of HCV-EGFR modulation and its impact on liver disease 
development. HCV binding to the HCV entry receptor complex (i.e. CD81, CLDN1) at the cell 
surface induces EGFR phosphorylation and downstream signaling. EGFR activity is prolonged 
by the NS5A-mediated perturbation of EGFR internalization and degradation. As a consequence, 
prolonged EGFR activity is associated with an increased hepatocyte proliferation, HSCs 
activation, fibrogenesis and a dampened antiviral response via modulation of STAT3. Groepper 
et al., (colored pathway) demonstrated that HCV replication enhances the expression of CXCR2 
ligands (e.g. CXCL8) by intermediary of an EGF-dependent mechanism and activation of the 
NF-κB signaling pathway. This is further favored via the proteolytic cleavage of TC-PTP by 
NS3/4A, resulting in increased EGFR activation. Upon EGF stimulation, the production of 
CXCL8 during HCV replication promotes the recruitment of neutrophils.  
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